NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Want to cut your energy bills? Here’s how five experts are doing it 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
BOTHELL, Wash., March 27, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) today announced that it will host a conference call and simultaneous webcast Monday, March 28, 2016, at 8:30 a.m. ET, to review top-line data from its Phase 2b clinical trial evaluating ALD403 in patients with chronic migraine and top-line data from its Phase 1 clinical trial evaluating multiple doses of ALD403 through various modes of administration in healthy volunteers.
Conference Call Details
The live call may be accessed by dialing 877-430-4657 for domestic callers or 484-756-4339 for international callers, and providing conference ID number 80096426.
The webcast, with slides, will be broadcast live on the Events & Presentations page of the Investors section of Alder’s website at www.alderbio.com and will be available for replay following the call for 30 days.
Media Contacts: David Schull or Lena Evans Russo Partners, LLC (212) 845-4271 (212) 845-4262 [email protected] [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals (425) 408-8032 [email protected]
